TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34100744

Group type: EXPERIMENTAL
Intervention: Gelfoam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intratympanic injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall recovery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Slight recovery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Marked recovery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Complete recovery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 40
Study: 34107336

Group type: EXPERIMENTAL
Intervention: Group sizes of 3-10 participants
Number of subjects: 64

Group type: COMPARATOR
Intervention: Group sizes larger than six
Number of subjects: 64
Study: 32044587

Group type: EXPERIMENTAL
Intervention: Repetition Priming (RP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antipriming (AP)
Number of subjects: 0
Study: 36131137

Group type: EXPERIMENTAL
Intervention: ILR + 24 h-Holter monitoring
Number of subjects: 25

Group type: COMPARATOR
Intervention: 24 h-Holter monitoring alone
Number of subjects: 25
Study: 33170417

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) at 120 mg/kg/day as a 1-h drip infusion 3 times a day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ) at 360 mg/kg/day as a 1-h drip infusion 4 times a day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ) in patients ≥ 15 years of age
Number of subjects: 99
Study: 32479686

Group type: EXPERIMENTAL
Intervention: Predialysis chronic kidney disease
Number of subjects: 16655

Group type: COMPARATOR
Intervention: Non-chronic kidney disease (control group)
Number of subjects: 16655

Group type: EXPERIMENTAL
Intervention: Predialysis chronic kidney disease with any comorbidity
Number of subjects: 16655
Study: 35129469

Group type: EXPERIMENTAL
Intervention: N-Acetyl-Cysteine (NAC) 1200 mg twice-daily for up to 5 days postoperatively
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: N-Acetyl-Cysteine (NAC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 34899429

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 79
Study: 34910624

Group type: EXPERIMENTAL
Intervention: Sleep Well! intervention
Number of subjects: 15
Study: 34040191

Group type: EXPERIMENTAL
Intervention: Genetic testing for FH (n = 160)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care with lipid testing alone (n = 80)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Pathogenic variant group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: No pathogenic variant group
Number of subjects: 240
Study: 35101523

Group type: EXPERIMENTAL
Intervention: Oral rapamycin (6 mg) prior to IV ketamine (0.5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo prior to IV ketamine (0.5 mg/kg)
Number of subjects: 20
Study: 33545982

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 35980956

Group type: EXPERIMENTAL
Intervention: Sleep extension (10 hours of sleep)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Active recovery session (CON)
Number of subjects: 10
Study: 34069369

Group type: EXPERIMENTAL
Intervention: Smart-ring CC feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-feedback
Number of subjects: 0
Study: 35964909

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg, oral, once a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (oral, once a day)
Number of subjects: 60
Study: 33214586

Group type: EXPERIMENTAL
Intervention: Alcohol group (n=88; receiving a drink with 3 cl alcohol)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sober control group (n=89; receiving a drink with just some alcohol drops)
Number of subjects: 177
Study: 35926004

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation program (18 sessions, 3 sessions/week)
Number of subjects: 68
Study: 34574572

Group type: EXPERIMENTAL
Intervention: High-impact exercise (HiEx)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: High-impact exercise with various directions (HiExVi)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HiInEx)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Sham exercise (ShEx)
Number of subjects: 174
Study: 35372024

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 2000 stimuli)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 41
Study: 33183774

Group type: EXPERIMENTAL
Intervention: CHX conditioning and SB2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MDP conditioning and SB2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined CHX and MDP conditioning and SB2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Direct bonding with SBU
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CHX conditioning and SBU
Number of subjects: 6

Group type: COMPARATOR
Intervention: Direct bonding with SB2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Water storage for 6 months
Number of subjects: 6
Study: 35701782

Group type: EXPERIMENTAL
Intervention: Self video feedback group (SVFG)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Expert-assisted video feedback group (EVFG)
Number of subjects: 89
Study: 32476255

Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: glimepiride (1 mg)
Number of subjects: 46
Study: 35329797

Group type: EXPERIMENTAL
Intervention: DiaTOHC
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 93
Study: 33683177

Group type: EXPERIMENTAL
Intervention: Kangaroo care provided with Sarbebe dress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care without Sarbebe dress)
Number of subjects: 0
Study: 33826539

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: High-sensitivity CRP ≥2 mg/dL
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Family history of premature coronary artery disease
Number of subjects: 1005
Study: 35675108

Group type: EXPERIMENTAL
Intervention: Home visit intervention (n=335)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Phone call intervention (n=334)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Standard of care (n=356)
Number of subjects: 1025
Study: 32507443

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham dry needling (sham DN)
Number of subjects: 30
Study: 33387165

Group type: EXPERIMENTAL
Intervention: Study without Stress (Cognitive Behavioural Therapy program)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care condition (Control)
Number of subjects: 56
Study: 34666179

Group type: EXPERIMENTAL
Intervention: FLASH Navigation System
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3D Fluoroscopy Navigation System
Number of subjects: 90
Study: 33409558

Group type: EXPERIMENTAL
Intervention: Yfiler™ Plus multiplex kit
Number of subjects: 539
Study: 35964947

Group type: EXPERIMENTAL
Intervention: Low-flow anesthesia (Group L)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-flow anesthesia (Group L) in smokers
Number of subjects: 64

Group type: COMPARATOR
Intervention: High-flow anesthesia (Group H)
Number of subjects: 64
Study: 33386797

Group type: EXPERIMENTAL
Intervention: Sacubitril valsartan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Perindopril
Number of subjects: 80
Study: 32546490

Group type: EXPERIMENTAL
Intervention: Amoxicillin (750 mg three times daily for 100 days)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amoxicillin (in those with type I Modic changes)
Number of subjects: 180
Study: 35703293

Group type: EXPERIMENTAL
Intervention: C-LIFE (cardiac rehabilitation-based lifestyle program)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: C-LIFE
Number of subjects: 140

Group type: COMPARATOR
Intervention: SEPA (standardized education and physician advice)
Number of subjects: 140
Study: 34410238

Group type: EXPERIMENTAL
Intervention: Role play method (cases)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional teaching methodology (controls)
Number of subjects: 107
Study: 32985509

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sensory-Motor Training (SMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bone Morphogenic Proteins (BMP)
Number of subjects: 60
Study: 34252378

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily orally for 14 days) plus standard care
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 292
Study: 32675483

Group type: EXPERIMENTAL
Intervention: Kono-S anastomosis
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 79
Study: 35788355

Group type: EXPERIMENTAL
Intervention: Rh-endostatin combined with WBRT
Number of subjects: 43

Group type: COMPARATOR
Intervention: Radiation group (WBRT only)
Number of subjects: 43
Study: 33990637

Group type: EXPERIMENTAL
Intervention: Metal Artifact Reduction (MAR) algorithm applied to CT scans
Number of subjects: 30

Group type: COMPARATOR
Intervention: Original CT scans without MAR
Number of subjects: 30
Study: 32859157

Group type: EXPERIMENTAL
Intervention: MARS-intervention (care-as-usual plus the MARS-intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 0
Study: 616874113

Group type: EXPERIMENTAL
Intervention: Intensive non‐randomized programme with a strict vegetarian diet
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Moderate randomized trial following a Mediterranean‐style diet
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group for intensive programme
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group for moderate programme
Number of subjects: 179
Study: 35168635

Group type: EXPERIMENTAL
Intervention: Online parent-led intervention
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Usual school practice
Number of subjects: 1080
Study: 34316168

Group type: EXPERIMENTAL
Intervention: Delirium prevention bundle protocol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care protocol
Number of subjects: 50
Study: 36498611

Group type: EXPERIMENTAL
Intervention: RA.DI.CA splint therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stabilization splint therapy
Number of subjects: 30
Study: 32154887

Group type: EXPERIMENTAL
Intervention: Protocol-guided individualized nutritional support to reach protein and energy goals
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 1950
Study: 35366092

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of caffeine
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3 mg/kg of cellulose (placebo)
Number of subjects: 15
Study: 34010616

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily for 24 months
Number of subjects: 5530

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily for 24 months
Number of subjects: 5530
Study: 32708898

Group type: EXPERIMENTAL
Intervention: Auditory feedback
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 31
Study: 36053958

Group type: EXPERIMENTAL
Intervention: Breastfeeding during OGTT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Avoiding breastfeeding during OGTT
Number of subjects: 20
Study: 32354234

Group type: EXPERIMENTAL
Intervention: Cognitive Flexibility in Aphasia Therapy (CFAT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional aphasia therapy
Number of subjects: 10
Study: 36250371

Group type: COMPARATOR
Intervention: Probiotic treatment (multi-strain probiotics including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, Streptococcus thermophilus) for 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks.
Number of subjects: 0
Study: 32738599

Group type: EXPERIMENTAL
Intervention: Regimen 1 (IRX-2 cytokines)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regimen 2 (Control, without IRX-2 cytokines)
Number of subjects: 96
Study: 33988477

Group type: EXPERIMENTAL
Intervention: Marathon shoes (Adidas Adizero 3)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Track spikes (Nike Zoom Matumbo 3)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both shoe conditions
Number of subjects: 5
Study: 32205642

Group type: EXPERIMENTAL
Intervention: 24-hour feeding after endoscopic hemostasis
Number of subjects: 209

Group type: COMPARATOR
Intervention: 48-hour feeding after endoscopic hemostasis
Number of subjects: 209
Study: 36404343

Group type: EXPERIMENTAL
Intervention: ATRA-ATO
Number of subjects: 128
Study: 33513232

Group type: EXPERIMENTAL
Intervention: Very early mobilization (within 24 hours from stroke onset)
Number of subjects: 6033

Group type: EXPERIMENTAL
Intervention: Early mobilization (between 24 and 72 hours poststroke)
Number of subjects: 6033

Group type: COMPARATOR
Intervention: Late mobilization (after 72 hours poststroke)
Number of subjects: 6033

Group type: EXPERIMENTAL
Intervention: Very early mobilization
Number of subjects: 6033

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 6033

Group type: COMPARATOR
Intervention: Late mobilization
Number of subjects: 6033
Study: 32149693

Group type: EXPERIMENTAL
Intervention: Resting state EEG functional connectivity measures using Phase-Lag-Index processing algorithm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Application of regression coefficients to connectivity measures from the test-set
Number of subjects: 10
Study: 33724638

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: MSBase registry (real-world cohort)
Number of subjects: 0
Study: 33285649

Group type: EXPERIMENTAL
Intervention: Active-assisted robotic therapy (n=6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Active-unassisted robotic therapy (n=8)
Number of subjects: 14
Study: 32247531

Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion for 120 minutes
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 1.5 mU/kg/minute for 60 minutes
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 0.5 mU/kg/minute for 60 minutes
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 3.0 mU/kg/minute for 60 minutes
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 1.5 mU/kg/minute for 60 minutes in metabolic syndrome and T2DM participants
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion for 120 minutes following revascularization for STEMI
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard care following revascularization for STEMI
Number of subjects: 85
Study: 34816585

Group type: EXPERIMENTAL
Intervention: TRAR gene classifier
Number of subjects: 350
Study: 33234812

Group type: EXPERIMENTAL
Intervention: Water-based group (n=20; 30 min of seated resting in a heated swimming pool at 30-32 °C)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Land-based group (n=15; 30 min of seated resting in a quiet room at 21-23 °C)
Number of subjects: 35
Study: 36037565

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 50 mg blackberry powder (BG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chewing gum containing 700 mg xylitol (CG)
Number of subjects: 50
Study: 33737296

Group type: EXPERIMENTAL
Intervention: Genetically inferred telomere length
Number of subjects: 20949
Study: 36457207

Group type: EXPERIMENTAL
Intervention: Innovator brand itraconazole 100 mg twice a day for 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multinational brand itraconazole 100 mg twice a day for 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Local generic brand itraconazole 100 mg twice a day for 4 weeks
Number of subjects: 100
Study: 34900928

Group type: EXPERIMENTAL
Intervention: Collective efficacy beliefs questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absence of appreciation and support in the psychosocial environment
Number of subjects: 0
Study: 34374086

Group type: EXPERIMENTAL
Intervention: Fremanezumab (225 mg, three monthly doses)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study: 32970574

Group type: EXPERIMENTAL
Intervention: Point-of-sale naloxone availability
Number of subjects: 98

Group type: COMPARATOR
Intervention: Chain pharmacies
Number of subjects: 98

Group type: COMPARATOR
Intervention: Independent pharmacies
Number of subjects: 98

Group type: COMPARATOR
Intervention: Rural areas
Number of subjects: 98

Group type: COMPARATOR
Intervention: Statutory awareness
Number of subjects: 98
Study: 35128781

Group type: EXPERIMENTAL
Intervention: High-speed rotational atherectomy (RA)
Number of subjects: 440
Study: 33709937

Group type: EXPERIMENTAL
Intervention: Web-based unguided self-help and psychoeducation (AdultCan RCT)
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Web-based therapist-supported cognitive behavioral therapy (Heart RCT)
Number of subjects: 2360

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Reminders for questionnaire completion
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: No reminder
Number of subjects: 2360
Study: 35635180

Group type: EXPERIMENTAL
Intervention: Breathing exercises
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control (standardized enhanced recovery strategies without breathing exercises)
Number of subjects: 264
Study: 33764654

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.25 mg/kg/dose)
Number of subjects: 287

Group type: COMPARATOR
Intervention: High-dose dexamethasone (0.5 mg/kg/dose)
Number of subjects: 287
Study: 32201441

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 60
Study: 35696440

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including physician training in risk-based treatment, subsidized losartan-HCTZ single-pill combination medications, nurse training in motivational conversations, and telephone follow-ups.
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 916

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 916
Study: 34187701

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation
Number of subjects: 130687

Group type: EXPERIMENTAL
Intervention: Genetically predicted consumption of alcohol
Number of subjects: 130687

Group type: EXPERIMENTAL
Intervention: Genetically predicted consumption of coffee
Number of subjects: 130687
Study: 32733948

Group type: EXPERIMENTAL
Intervention: Nomogram based on independent prognostic factors (age, marital status, grade, tumor size, AJCC 8th edition T stage and M stage, LODDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calibration curve and ROC curve validation
Number of subjects: 0
Study: 36418566

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 175
Study: 35129523

Group type: EXPERIMENTAL
Intervention: Early surgery (surgery within 6 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Endoscopy-first approach
Number of subjects: 88
Study: 33009489

Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone (AAP) - abiraterone 1000 mg/day plus prednisone 10 mg/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Enzalutamide - 160 mg/day
Number of subjects: 51
Study: 36342811

Group type: EXPERIMENTAL
Intervention: Lianhua Qingwen capsule (LH), 4 capsules, thrice daily for 14 days
Number of subjects: 120
Study: 32466729

Group type: EXPERIMENTAL
Intervention: Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease events
Number of subjects: 15076

Group type: EXPERIMENTAL
Intervention: Computable phenotype implementation
Number of subjects: 15076

Group type: EXPERIMENTAL
Intervention: Recruitment methods
Number of subjects: 15076
Study: 32646266

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (Texas Medication Algorithm Project)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Higher load of life events and difficulties (LEDs) related to entrapment and humiliation
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Higher levels of external entrapment (Entrapment Scale)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Demographic and clinical data, severity of depression, social ranking, evolution informed variables, LEDs, childhood maltreatment
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: External entrapment
Number of subjects: 139
Study: 32804892

Group type: EXPERIMENTAL
Intervention: Combined treatment with FMR and TFL
Number of subjects: 25

Group type: COMPARATOR
Intervention: FMR alone
Number of subjects: 25
Study: 32907282

Group type: EXPERIMENTAL
Intervention: HepB (CHO)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: HepB (SC)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Pre-booster anti-HBs between 2.5 mIU/ml and 10 mIU/ml
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 322

Group type: COMPARATOR
Intervention: Anti-HBs <2.5 mIU/ml
Number of subjects: 322

Group type: COMPARATOR
Intervention: Anti-HBs 2.5-10 mIU/ml
Number of subjects: 322
Study: 34187068

Group type: EXPERIMENTAL
Intervention: Sutured-portal group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Open-portal group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 34886221

Group type: EXPERIMENTAL
Intervention: Verbal–Visual feedback (VER&VIS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Verbal feedback (VER)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Visual feedback (VIS)
Number of subjects: 61